Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: Results of a population-based European collaborative follow-up study

Digestion

Volumn 75, Issue 2-3, 2007, Pages 113-121

  Katsanos, K H ^a   Vermeire, S ^b   Christodoulou, D K ^a   Riis, L ^c   Wolters, F ^d   Odes, S ^e   Freitas, J ^f   Hoie, Ole ^g   Beltrami, Marina ^h   Fornaciari, G ^h   Clofent, J ⁱ   Bodini, P ^j   Vatn, M ^k   Nunes, Paula Borralho ^f   Moum, B ^l   Munkholm, P ^c   Limonard, C ^m   Stockbrugger, R ^d   Rutgeerts, P ^b   Tsianos, E V ^a,n  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f HOSPITAL GARCIA DE ORTA   (Portugal)

^g Sørlandet Sykehus ^*  (Norway)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ University Hospital of Vigo   (Spain)

^j CREMONA HOSPITAL   (Italy)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l AKER UNIVERSITY HOSPITAL   (Norway)

^m Centre for Data and Information Management   (Netherlands)

ⁿ UNIVERSITY OF IOANNINA   (Greece)

more..

Author keywords

Cancer; Crohn's disease; Dysplasia; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CANCER DIAGNOSIS; COHORT ANALYSIS; COLORECTAL CANCER; CROHN DISEASE; DYSPLASIA; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; INTESTINE CANCER; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOPSY; CHI-SQUARE DISTRIBUTION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK;

EID: 34548316885     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104731     Document Type: Article

References (54)

1. Bansal P, Sonnenberg A: Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996;91:44-48.
2. Brostrom O, Lofberg R, Nordenvall B, Ost A, Hellers G: The risk of colorectal cancer in ulcerative colitis: an epidemiologic study. Scand J Gastroenterol 1987;22:1193-1199.
3. Jackman RJ, Stickler GB: Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971;285:17-21.
4. Ekbom A, Helmick C, Zack M, Adami HO: Increased risk of large bowel cancer in Crohn's disease with colonic involvement. Lancet 1990;336:357-359.
5. Ekbom A: Risk factors and distinguishing features of cancer in IBD. Inflamm Bowel Dis 1998;4:235-243.
6. Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH: A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 1981;48:2742-2745.
7. Lashner BA: Risk factors for small bowel cancer in Crohn's disease. Dig Dis Sci 1992;37:1179-1184.
8. Munkholm P, Langholz E, Davidsen M, Binder V: Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105:1716-1723.
9. Ekbom A, Helmick C, Zack M, Adami HO: Ulcerative colitis and colorectal cancer. A population based study. N Engl J Med 1990;323:1228-1233.
10. Katsanos KH, Christodoulou DK, Ioachim E, Michail M, Tsianos G, Agnantis N, Tsianos EV: Inflammatory bowel disease-related dysplasia and cancer: a referral center study in northwestern Greece. Eur J Intern Med 2005;16:170-175.
11. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TIA: Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-2729.
12. Greenstein AJ, Gennuso R, Sachar D, Heimann T, Smith H, Janowitz HD, et al: Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914-2921.
13. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535.
14. Velayos FS, Terdiman JP, Walsh JM: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2005;100:1345-1353.
15. Shivananda S, Lennard-Jones JE, Logan RF, Fear N, Price A, Carpenter L: Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on inflammatory bowel disease. Gut 1996;39:690-697.
16. Stockbrugger RW, Russel MG, van Blankenstein M, Shivananda S: EC-IBD: a European effort in inflammatory bowel disease. Eur J Intern Med 2000;11:187-190.
17. Bai M, Katsanos KH, Economou M, Kamina S, Bali C, Briasoulis E, Kappas A, Agnanti N, Tsianos EV: Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand J Gastroenterol 2006;41:866-869.
18. Katsanos KH, Christodoulou D, Zioga A, Dimou S, Tsianos EV: Cutaneous nevi pigmentosus during infliximab therapy in a Crohn's disease patient: fallacy or coincidence? Inflamm Bowel Dis 2003;9:279.
19. Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastorenterol 1989;170:2-6.
20. Witte J, Shivananda S, Lennard-Jones JE, Beltrami M, Politi P, Bonanomi A, et al: Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand J Gastroenterol 2000;12:1272-1277.
21. Wolters F, van Zeijl G, Sijbrandij J, Wessels F, O'Morain C, Limonard C, et al: Internet-based data inclusion in a population-based European collaborative follow-up study of IBD patients: description of methods used and analysis of factors influencing response rates. World J Gastroenterol 2005;11:7152-7158.
22. Wolters F, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al: Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006;55:510-518.
23. WHO: The Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10). Geneva, WHO, 1992.
24. Breslow NE, Day NE: Statistical Methods in Cancer Research. Vol 2: The Design and Analysis of Cohort Studies. Lyon, IARC, 1986, pp 48-79.
25. Travis SPL: Insurance risks for patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther 1997;11:51-59.
26. Jess T, Loftus EV Jr, Velayos FS, Scott Harmsen W, Zinsmeister AR, Smyrk TC, et al: Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 2006;130:1039-1046.
27. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al: Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-1038.
28. Nordenholtz KE, Stowe SP, Stormont JM, Stowe MM, Chessin LN, Shah AN, et al: The cause of death in inflammatory bowel disease: a comparison of death certificates and hospital charts in Rochester, New York. Am J Gastroenterol 1995;90:927-932.
29. Palli D, Trallori G, Saieva C, et al: General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence study. Gut 1998;42:175-179.
30. Viscido A, Bagnardi V, Sturniolo GC, et al: Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study. Dig Liver Dis 2001;33:686-692.
31. Biasco G, Rossini FP, Hakim R, et al: Cancer surveillance in ulcerative colitis: critical analysis of long term prospective programme. Dig Liver Dis 2002;34:339-342.
32. Eaden JA, Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002;51:V10-V12.
33. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson P-G, Ekbom A: Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998;42:711-714.
34. Lennard-Jones JE, Morson BC, Ritchie JK, Williams CB: Cancer surveillance in ulcerative colitis: experience over 15 years. Lancet 1983;2:149-152.
35. Rhodes JM: Surveillance for colitis-associated cancer: we cannot stop now. Dig Liver Dis 2002;34:319-321.
36. Sjoqvist U, Lofberg R: Endoscopic surveillance in chronic inflammatory bowel disease: background, methods and practical considerations. Acta Endosc 1997;27:129-143.
37. Collins RH Jr, Feldman M, Fordtran JS: Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis: a critical review. N Engl J Med 1987;316:1654-1658.
38. Christodoulou D, Skopelitou A, Katsanos KH, Katsios C, Kappas A, Agnantis N, Tsianos EV: Small bowel adenocarcinoma as first manifestation of Crohn's disease. Eur J Gastroenterol Hepatol 2002;14:805-810.
39. Skopelitou A, Katsanos KH, Michail M, Mitselou A, Tsianos EV: Immunohistochemical expression of FHIT gene product in inflammatory bowel disease;significance and correlation with clinicopathological data. Eur J Gastroenterol Hepatol 2003;15:665-673.
40. Leidenius MHK, Farkkila MA, Karkkainen P, Taskinen EI, Kellokumpu IH, Hockerstedt KAV: Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol 1997;32:706-711.
41. Marchesa P, Lashner B, Lavery IC, et al: The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92:1285-1288.
42. Moody GA, Jayanthi V, Probert CSJ, Mac Kay H, Mayberry JF: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-1183.
43. Christodoulou DK, Katsanos KH, Baltayannis G, Tzabouras N, Tsianos EV: A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece. Hepatogastroenterology 2003;50:1021-1024.
44. Connel WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones J: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-1252.
45. Brown SL, Greene MH, Gershon SK, et al: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-3158.
46. Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999;5:119-133.
47. Vatn MH, Elgio K, Bergan A: Distribution of dysplasia in ulcerative colitis. Scand J Gastroenterol 1984;19:893-895.
48. Blomqvist P, Ekbom A: Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32:1134-1139.
49. Binder V, Hendriksen C, Kreiner S: Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:146-150.
50. Lindgren A, Wallerstedt S, Olson R: Prevalence of Crohn's disease and simultaneous occurrence of extraintestinal complications and cancer. Scand J Gastroenterol 1996;31:74-78.
51. Tsianos EV, Katsanos KH, Christodoulou D, Dimoliatis I, Logan RF: Continuing low incidence of Crohn's disease in northwest Greece. Dig Liver Dis 2003;35:99-103.
52. Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan RFA: Incidence of inflammatory bowel disease in north-west Greece: rarity of Crohn's disease in an area where ulcerative colitis is common. Gut 1994;35:369-372.
53. Snapper SB, Syngal S, Friedman LS: Ulcerative colitis and colon cancer: more controversy than clarity. Dig Dis Sci 1998;16:81-87.
54. Tsianos EV: The risk of cancer in inflammatory bowel disease. Eur J Intern Med 2000;11:75-78.